X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells $17,862.32 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Paula Ragan sold 31,897 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $0.56, for a total transaction of $17,862.32. Following the sale, the chief executive officer now directly owns 1,025,816 shares in the company, valued at $574,456.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Paula Ragan also recently made the following trade(s):

• On Monday, October 7th, Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock. The shares were sold at an average price of $0.55, for a total value of $131,689.80.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $0.50 on Friday. X4 Pharmaceuticals, Inc. has a 12-month low of $0.47 and a 12-month high of $1.60. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.07 and a quick ratio of 6.04. The firm has a market capitalization of $83.41 million, a price-to-earnings ratio of -0.71 and a beta of 0.36. The business has a 50 day simple moving average of $0.65 and a 200 day simple moving average of $0.86.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The business had revenue of $0.56 million during the quarter, compared to the consensus estimate of $52.98 million. During the same period in the previous year, the business earned ($0.33) EPS. On average, equities research analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of X4 Pharmaceuticals in a report on Friday, June 28th.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its position in shares of X4 Pharmaceuticals by 46.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after buying an additional 12,514 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of X4 Pharmaceuticals in the third quarter valued at approximately $37,000. XTX Topco Ltd acquired a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $65,000. Rhumbline Advisers raised its holdings in X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after purchasing an additional 23,831 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares in the last quarter. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.